You are now leaving the Lilly Medical website
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical
If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Olumiant® (baricitinib) tablets
1mg, 2mg, 4mgbaricitinib
1mg, 2mg, 4mgOlumiant® (baricitinib) tablets
1mg, 2mg, 4mgbaricitinib
1mg, 2mg, 4mgThis information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
What is the recommended dose of OLUMIANT® (baricitinib) for pediatric patients with severe alopecia areata?
The recommended dosage of baricitinib for adults and pediatric patients 12 years of age and older with severe alopecia areata is 2 mg once daily orally, with or without food. Increase to 4 mg once daily if the response to treatment is not adequate.
See important safety information, including boxed warning, in the attached prescribing information.
What is the indication for baricitinib in adolescent patients with severe alopecia areata?
Baricitinib is indicated for the treatment of severe alopecia areata in adults and pediatric patients 12 years of age and older.1
The recommended dosage of baricitinib for adults and pediatric patients 12 years of age and older is 2 mg once daily orally, with or without food. Increase to 4 mg once daily if the response to treatment is not adequate.1
For adults and pediatric patients 12 years of age and older with nearly complete or complete scalp hair loss, with or without substantial eyelash or eyebrow hair loss, consider treating with 4 mg once daily, with or without food. Once patients achieve an adequate response to treatment with 4 mg, decrease the dosage to 2 mg once daily.1
Baricitinib is not recommended for use in combination with other Janus kinase (JAK) inhibitors, biologic immunomodulators, cyclosporine or other potent immunosuppressants.1
How is baricitinib administered in pediatric patients with alopecia areata?
Baricitinib tablets are given orally with or without food.1
Alternate Administration
For patients who are unable to swallow whole tablets, an alternative mode of administration, oral dispersion, may be considered.1
The 1-mg, 2-mg, or 4-mg baricitinib tablet(s), or any combination of tablets necessary to achieve the desired dose up to 4-mg, may be placed in a container with approximately 10 mL (5 mL minimum) of room temperature water, dispersed by gently swirling the tablet(s) and immediately taken orally.1
The container should be rinsed with an additional 10 mL (5 mL minimum) of room temperature water and the entire contents swallowed by the patient.1
What dose modification is recommended for baricitinib in patients with renal impairment?
The recommended dosage of baricitinib in patients with moderate renal impairment (estimated glomerular filtration rate between 30 and <60 mL/min/1.73 m²) should be reduced by half the recommended dose.1
What dose modification is recommended for baricitinib in patients with alopecia areata because of drug interactions?
Baricitinib exposure is increased when baricitinib is co-administered with strong organic anion transporter 3 inhibitors (such as probenecid), hence the dosage of baricitinib should be reduced by half the recommended dose.1
Enclosed Prescribing Information
OLUMIANT (baricitinib) tablets, for oral use, Lilly
Reference
- Olumiant [package insert]. Indianapolis, IN: Eli Lilly and Company; 2026.
Date of Last Review: October 06, 2026